Literature DB >> 20589141

Screening for hepatitis C among HIV positive patients at Mulago hospital in Uganda.

V Walusansa1, M Kagimu.   

Abstract

BACKGROUND: In industrialized countries with more resources, it is recommended that HIV infected patients should be screened for hepatitis C virus (HCV) on entry into the health care system. Implementation of these guidelines in a country like Uganda with limited resources requires some modification after taking into account the prevailing circumstances. These include the prevalence of HCV in HIV positive patients and the cost of HCV testing.
OBJECTIVE: The objective of the study was to estimate the prevalence of HCV in HIV positive patients.
METHODS: This was a cross sectional study among HIV positive outpatients in Mulago hospital. HCV screening was done using anti-HCV Enzyme Immuno Assay (Roche Diagnostics)
RESULTS: Between October 2003 and February 2004, one hundred and twenty two HIV positive patients were enrolled into the study with a mean age of 33.9 years. There were more females 81 (66.4%) than males. Only 4 patients had anti-HCV, giving an estimated HCV prevalence of 3.3%.
CONCLUSION: In view of the low HCV prevalence found in our study and similar studies and considering the high cost of HCV screening, routine HCV testing cannot be recommended among all HIV positive patients in our health care settings with limited resources. We recommend that HCV screening be limited to investigating HIV positive patients with features suggestive of liver disease in order to identify HCV as a possible cause.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20589141      PMCID: PMC2887030     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  16 in total

1.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Authors:  M S Sulkowski; D L Thomas; R E Chaisson; R D Moore
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

2.  Hepatitis C virus antibody in HIV-1 infected Ugandan mothers.

Authors:  J B Jackson; L Guay; J Goldfarb; K Olness; C Ndugwa; F Mmiro; P Kataaha; J P Allain
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

3.  Anti-HCV false positivity in malaria.

Authors:  A Aceti; G Taliani; C de Bac; A Sebastiani
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

4.  Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome.

Authors:  Massimo Puoti; Carlo Torti; Diego Ripamonti; Francesco Castelli; Serena Zaltron; Barbara Zanini; Angiola Spinetti; Valeria Putzolu; Salvatore Casari; Lina Tomasoni; Eugenia Quiros-Roldan; Maurizio Favret; Luisa Berchich; Piergiovanni Grigolato; Francesco Callea; Giampiero Carosi
Journal:  J Acquir Immune Defic Syndr       Date:  2003-03-01       Impact factor: 3.731

Review 5.  Viral hepatitis.

Authors:  F A Okoth
Journal:  East Afr Med J       Date:  1996-05

Review 6.  HIV/HCV co-infection: the magnitude of the problem.

Authors:  E Balestra; S Aquaro; C F Perno
Journal:  J Biol Regul Homeost Agents       Date:  2003 Apr-Jun       Impact factor: 1.711

7.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-16

Review 8.  Hepatitis C in the HIV-Infected Person.

Authors:  Mark S Sulkowski; David L Thomas
Journal:  Ann Intern Med       Date:  2003-02-04       Impact factor: 25.391

9.  Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

Authors:  Jonathan E Kaplan; Henry Masur; King K Holmes
Journal:  MMWR Recomm Rep       Date:  2002-06-14

Review 10.  Acute hepatitis C.

Authors:  Anurag Maheshwari; Stuart Ray; Paul J Thuluvath
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

View more
  10 in total

1.  High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda.

Authors:  Caroline E Mullis; Oliver Laeyendecker; Steven J Reynolds; Ponsiano Ocama; Jeffrey Quinn; Iga Boaz; Ronald H Gray; Gregory D Kirk; David L Thomas; Thomas C Quinn; Lara Stabinski
Journal:  Clin Infect Dis       Date:  2013-09-18       Impact factor: 9.079

2.  Characterisation of hepatitis C virus genotype among blood donors at the regional blood transfusion centre of Ouagadougou, Burkina Faso.

Authors:  Moctar Tokèda Abdoul Zeba; Mahamoudou Sanou; Cyrille Bisseye; Alice Kiba; Bolni Marius Nagalo; Florencia Wendkuuni Djigma; Tegwindé Rebecca Compaoré; Yacouba Koumpingnin Nebié; Kisito Kienou; Tani Sagna; Virginio Pietra; Rémy Moret; Jacques Simporé
Journal:  Blood Transfus       Date:  2014-01       Impact factor: 3.443

3.  Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.

Authors:  Noeline Nakasujja; Sachiko Miyahara; Scott Evans; Anthony Lee; Seggane Musisi; Elly Katabira; Kevin Robertson; Allan Ronald; David B Clifford; Ned Sacktor
Journal:  Neurology       Date:  2012-12-26       Impact factor: 9.910

4.  Sero-prevalence and associated risk factors for hepatitis C virus infection among voluntary counseling testing and anti retroviral treatment clinic attendants in Adwa hospital, northern Ethiopia.

Authors:  Ataklti Hailu Atsbaha; Tsehaye Asmelash Dejen; Rashmi Belodu; Konjit Getachew; Muthupandian Saravanan; Araya Gebreyesus Wasihun
Journal:  BMC Res Notes       Date:  2016-02-23

Review 5.  HIV, HBV and HCV Coinfection Prevalence in Iran--A Systematic Review and Meta-Analysis.

Authors:  Fahimeh Bagheri Amiri; Ehsan Mostafavi; Ali Mirzazadeh
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

6.  COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.

Authors:  Billy Nsubuga Mayanja; Ivan Kasamba; Jonathan Levin; Ivan Namakoola; Patrick Kazooba; Jackson Were; Pontiano Kaleebu; Paula Munderi
Journal:  AIDS Res Ther       Date:  2017-05-04       Impact factor: 2.250

7.  Detection and analysis of hepatitis C virus in HIV-infected patients in the Guangxi province of China.

Authors:  Shu-Zhi Wu; Jin-Lu Wei; Bin Xu; Peng-Hai Wei; Yan Yang; Bin Qin; Zhi-Chun Xie
Journal:  Exp Ther Med       Date:  2017-01-20       Impact factor: 2.447

8.  Hepatitis C virus and human immunodeficiency virus coinfection among attendants of voluntary counseling and testing centre and HIV follow up clinics in Mekelle Hospital.

Authors:  Haftom Hadush; Solomon Gebre-Selassie; Adane Mihret
Journal:  Pan Afr Med J       Date:  2013-03-18

9.  Evaluation of an antigen-antibody "combination" enzyme linked immunosorbent assay for diagnosis of hepatitis C virus infections.

Authors:  E O Odari; N L M Budambula; H Nitschko
Journal:  Ethiop J Health Sci       Date:  2014-10

10.  Prevalence and Factors Associated With Hepatitis B and C Co-Infection Among HIV-1-Infected Patients in Kenya.

Authors:  Duncan Ndegwa Maina; Andrew Kimanga Nyerere; Ruth Wambui Gicho; Joseph Maina Mwangi; Raphael Wekesa Lihana
Journal:  East Afr Health Res J       Date:  2017-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.